Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Vascular Surgery

  Free Subscription


Articles published in Am Heart J

Retrieve available abstracts of 223 articles:
HTML format



Single Articles


    March 2021
  1. FABRIS E, Ten Berg JM, Hermanides RS, Ottervanger JP, et al
    NT-proBNP level before primary PCI and risk of poor myocardial reperfusion: Insight from the On-TIME II trial.
    Am Heart J. 2021;233:78-85.
    PubMed     Abstract available


    February 2021
  2. PEREIRA NL, Avram R, So DY, Iturriaga E, et al
    Rationale and design of the TAILOR-PCI digital study: Transitioning a randomized controlled trial to a digital registry.
    Am Heart J. 2021;232:84-93.
    PubMed     Abstract available


  3. BRAIK N, Guedeney P, Behnes M, Desch S, et al
    Impact of chronic total occlusion and revascularization strategy in patients with infarct-related cardiogenic shock: A subanalysis of the culprit-shock trial.
    Am Heart J. 2021;232:185-193.
    PubMed     Abstract available


  4. LOTTES AE, Whatley EM, Royce SM, Bertges DJ, et al
    Important considerations for trials for peripheral arterial disease: Lessons learned from the paclitaxel mortality signal: A report on behalf of the registry assessment for peripheral interventional Devices (RAPID) Paclitaxel Pathways Program.
    Am Heart J. 2021;232:71-83.
    PubMed     Abstract available


    January 2021
  5. GE Z, Kan J, Gao XF, Kong XQ, et al
    Comparison of intravascular ultrasound-guided with angiography-guided double kissing crush stenting for patients with complex coronary bifurcation lesions: rationale and design of a prospective, randomized and multicenter DKCRUSH VIII trial.
    Am Heart J. 2021 Jan 16. pii: S0002-8703(21)00015.
    PubMed     Abstract available


  6. ZHAO Y, Sivaswamy A, Lee MK, Izadnegahdar M, et al
    A Feasibility Study for CODE-MI: High-Sensitivity Cardiac Troponin - Optimizing the Diagnosis of Acute Myocardial Infarction/Injury in Women.
    Am Heart J. 2021 Jan 15. pii: S0002-8703(21)00012.
    PubMed     Abstract available


  7. YANKEY GS, Jackson LR, Marts C, Chiswell K, et al
    African American-Caucasian American Differences in Aortic Valve Replacement in Patients with Severe Aortic Stenosis: Racial Differences in AVR.
    Am Heart J. 2021 Jan 13. pii: S0002-8703(21)00009.
    PubMed     Abstract available


  8. THIELE H, Freund A, Gimenez MR, de Waha-Thiele S, et al
    Extracorporeal life support in patients with acute myocardial infarction complicated by cardiogenic shock - Design and rationale of the ECLS-SHOCK trial.
    Am Heart J. 2021 Jan 8. pii: S0002-8703(21)00004.
    PubMed     Abstract available


  9. MARBACH JA, Wells G, Santo PD, So D, et al
    Acute Kidney Injury after Radial or Femoral Artery Access in ST-Segment Elevation Myocardial Infarction: AKI-SAFARI.
    Am Heart J. 2021 Jan 7. pii: S0002-8703(21)00001.
    PubMed     Abstract available


  10. FAGEL ND, Amoroso G, Vink MA, Slagboom T, et al
    An immediate or early invasive strategy in non-ST-elevation acute coronary syndrome: the OPTIMA-2 randomized controlled trial.
    Am Heart J. 2021 Jan 7. pii: S0002-8703(21)00003.
    PubMed     Abstract available


  11. VALGIMIGLI M, Cao D, Makkar RR, Bangalore S, et al
    Design and rationale of the XIENCE short DAPT clinical program: An assessment of the safety of 3-month and 1-month DAPT in patients at high bleeding risk undergoing PCI with an everolimus-eluting stent.
    Am Heart J. 2021;231:147-156.
    PubMed     Abstract available


    December 2020
  12. MALIK AO, Amin A, Kennedy K, Qintar M, et al
    Patient-centered contrast thresholds to reduce acute kidney injury in high-risk patients undergoing percutaneous coronary intervention.
    Am Heart J. 2020 Dec 23. pii: S0002-8703(20)30415.
    PubMed     Abstract available


  13. CHOUDHARY R, Kumari V
    Aspirin versus P2Y12 inhibitor-based monotherapy after percutaneous coronary intervention.
    Am Heart J. 2020;230:99.
    PubMed    


  14. KUNO T, Ueyama H, Takagi H, Bangalore S, et al
    Choosing between aspirin or P2Y12 monotherapy after short course of DAPT.
    Am Heart J. 2020;230:100.
    PubMed    


  15. JOYCE J, O'Leary ET, Mah DY, Harrild DM, et al
    Cardiac resynchronization therapy improves the ventricular function of patients with Fontan physiology.
    Am Heart J. 2020;230:82-92.
    PubMed     Abstract available


  16. DE LA PAZ A, Orgel R, Hartsell SE, Pauley E, et al
    Getting cardiogenic shock patients to the right place-How initial intensive care unit triage decisions impact processes of care and outcomes.
    Am Heart J. 2020;230:66-70.
    PubMed     Abstract available


    November 2020
  17. DAYAN V, Myers P
    Comparing apples and oranges and adding inches to meters: Is this the way to conduct rigorous meta-analyses of PCI versus CABG in left main coronary disease?
    Am Heart J. 2020;229:180-181.
    PubMed    


  18. KUNO T, Ueyama H, Rao SV, Cohen MG, et al
    Meta-analysis of PCI vs. CABG for left main disease revisited.
    Am Heart J. 2020;229:178-179.
    PubMed    


  19. YANNOPOULOS D, Kalra R, Kosmopoulos M, Walser E, et al
    Rationale and methods of the Advanced R(2)Eperfusion STrategies for Refractory Cardiac Arrest (ARREST) trial.
    Am Heart J. 2020;229:29-39.
    PubMed     Abstract available


    October 2020
  20. JAWITZ OK, Stebbins AS, Raman V, Alhanti B, et al
    Association between levosimendan, postoperative AKI, and mortality in cardiac surgery: Insights from the LEVO-CTS trial.
    Am Heart J. 2020 Oct 27. pii: S0002-8703(20)30352.
    PubMed     Abstract available


  21. JAWITZ OK, Cox ML, Ranney D, Williams JB, et al
    Outcomes following revascularization with radial artery bypass grafts: Insights from the PREVENT-IV trial.
    Am Heart J. 2020;228:91-97.
    PubMed     Abstract available


  22. LI Y, Wang X, Bao D, Liao Z, et al
    Optimal antiplatelet therapy for prevention of gastrointestinal injury evaluated by ANKON magnetically controlled capsule endoscopy: Rationale and design of the OPT-PEACE trial.
    Am Heart J. 2020;228:8-16.
    PubMed     Abstract available


    September 2020
  23. BIAGIONI RB, Lopes RD, Agati LB, Sacilotto R, et al
    Rationale and design for the study Apixaban versus ClopidoGRel on a background of aspirin in patient undergoing InfraPoPliteal angioplasty for critical limb ischemia: AGRIPPA trial.
    Am Heart J. 2020;227:100-106.
    PubMed     Abstract available


    August 2020
  24. LAURIDSEN MD, Rorth R, Lindholm MG, Kjaergaard J, et al
    Trends in first-time hospitalization, management, and short-term mortality in acute myocardial infarction-related cardiogenic shock from 2005-2017: A nationwide cohort study.
    Am Heart J. 2020 Aug 27. pii: S0002-8703(20)30242.
    PubMed     Abstract available


  25. GUTIERREZ JA, Heizer GM, Jones WS, Rockhold FW, et al
    CYP2C19 status and risk of major adverse cardiovascular events in peripheral artery disease: Insights from the EUCLID Trial.
    Am Heart J. 2020;229:118-120.
    PubMed    


  26. KANG DY, Ahn JM, Park H, Lee PH, et al
    Comparison of optical coherence tomography-guided versus intravascular ultrasound-guided percutaneous coronary intervention: Rationale and design of a randomized, controlled OCTIVUS trial.
    Am Heart J. 2020;228:72-80.
    PubMed     Abstract available


  27. SHLOFMITZ E, Torguson R, Mintz GS, Zhang C, et al
    The IMPact on Revascularization Outcomes of intraVascular ultrasound-guided treatment of complex lesions and Economic impact (IMPROVE) trial: Study design and rationale.
    Am Heart J. 2020;228:65-71.
    PubMed     Abstract available


  28. KATZ JN
    Back to the future-Are we ready for a randomized trial of surgical versus percutaneous revascularization in cardiogenic shock?
    Am Heart J. 2020;226:264-266.
    PubMed    


    July 2020
  29. STAHLI BE, Varbella F, Schwarz B, Nordbeck P, et al
    Rationale and design of the MULTISTARS AMI Trial: A randomized comparison of immediate versus staged complete revascularization in patients with ST-segment elevation myocardial infarction and multivessel disease.
    Am Heart J. 2020;228:98-108.
    PubMed     Abstract available


  30. PLOUMEN EH, Buiten RA, Doggen CJM, Stoel MG, et al
    New-generation drug-eluting coronary stents in octogenarians: Patient-level pooled analysis from the TWENTE I-IV trials.
    Am Heart J. 2020;228:109-115.
    PubMed     Abstract available


  31. LI Y, Jing Q, Wang B, Wang X, et al
    Extended antiplatelet therapy with clopidogrel alone versus clopidogrel plus aspirin after completion of 9- to 12-month dual antiplatelet therapy for acute coronary syndrome patients with both high bleeding and ischemic risk. Rationale and design of t
    Am Heart J. 2020;228:1-7.
    PubMed     Abstract available


  32. YU C, Liu C, Du J, Liu H, et al
    Smartphone-based application to improve medication adherence in patients after surgical coronary revascularization.
    Am Heart J. 2020;228:17-26.
    PubMed     Abstract available


  33. SILVAIN J, Cayla G, Beygui F, Range G, et al
    Blunting periprocedural myocardial necrosis: Rationale and design of the randomized ALPHEUS study.
    Am Heart J. 2020;225:27-37.
    PubMed     Abstract available


    June 2020
  34. YAN Y, Wang X, Guo J, Li Y, et al
    Rationale and design of the RIGHT trial: A multicenter, randomized, double-blind, placebo-controlled trial of anticoagulation prolongation versus no anticoagulation after primary percutaneous coronary intervention for ST-segment elevation myocardial i
    Am Heart J. 2020;227:19-30.
    PubMed     Abstract available


  35. DEN DEKKER WK, Van Mieghem NM, Bennett J, Sabate M, et al
    Percutaneous complete revascularization strategies using sirolimus-eluting biodegradable polymer-coated stents in patients presenting with acute coronary syndrome and multivessel disease: Rationale and design of the BIOVASC trial.
    Am Heart J. 2020;227:111-117.
    PubMed     Abstract available


  36. KUNO T, Ueyama H, Takagi H, Bangalore S, et al
    P2Y12 inhibitor monotherapy versus aspirin monotherapy after short-term dual antiplatelet therapy for percutaneous coronary intervention: Insights from a network meta-analysis of randomized trials.
    Am Heart J. 2020;227:82-90.
    PubMed     Abstract available


  37. KUNO T, Ueyama H, Rao SV, Cohen MG, et al
    Percutaneous coronary intervention or coronary artery bypass graft surgery for left main coronary artery disease: A meta-analysis of randomized trials.
    Am Heart J. 2020;227:9-10.
    PubMed     Abstract available


  38. LAMBERT LM, McCrindle BW, Pemberton VL, Hollenbeck-Pringle D, et al
    Longitudinal study of anthropometry in Fontan survivors: Pediatric Heart Network Fontan study.
    Am Heart J. 2020;224:192-200.
    PubMed     Abstract available


  39. ERHUN F, Kaplan RS, Narayanan VG, Brayton K, et al
    Are cost advantages from a modern Indian hospital transferable to the United States?
    Am Heart J. 2020;224:148-155.
    PubMed     Abstract available


    May 2020
  40. ARMSTRONG PW, Bogaerts K, Welsh R, Sinnaeve PR, et al
    The Second Strategic Reperfusion Early After Myocardial Infarction (STREAM-2) study optimizing pharmacoinvasive reperfusion strategy in older ST-elevation myocardial infarction patients.
    Am Heart J. 2020;226:140-146.
    PubMed     Abstract available


  41. SMILOWITZ NR, Galloway AC, Ohman EM, Rao SV, et al
    Coronary revascularization and circulatory support strategies in patients with myocardial infarction, multi-vessel coronary artery disease, and cardiogenic shock: Insights from an international survey.
    Am Heart J. 2020;225:55-59.
    PubMed     Abstract available


  42. MARQUIS-GRAVEL G, Huang Z, Zelenkofske SL, Lincoff AM, et al
    Interplay between PCI access site, anticoagulant agent, and bleeding: Insights from the REGULATE-PCI randomized trial.
    Am Heart J. 2020;223:84-86.
    PubMed    


  43. COSTA F, van Klaveren D, Colombo A, Feres F, et al
    A 4-item PRECISE-DAPT score for dual antiplatelet therapy duration decision-making.
    Am Heart J. 2020;223:44-47.
    PubMed     Abstract available


    April 2020
  44. GUEDENEY P, Thiele H, Kerneis M, Barthelemy O, et al
    Radial versus femoral artery access for percutaneous coronary artery intervention in patients with acute myocardial infarction and multivessel disease complicated by cardiogenic shock: Subanalysis from the CULPRIT-SHOCK trial.
    Am Heart J. 2020;225:60-68.
    PubMed     Abstract available


  45. LAINE M, Lemesle G, Burtey S, Cayla G, et al
    TicagRelor Or Clopidogrel in severe or terminal chronic kidney patients Undergoing PERcutaneous coronary intervention for acute coronary syndrome: The TROUPER trial.
    Am Heart J. 2020;225:19-26.
    PubMed     Abstract available


  46. DAN K, Shlofmitz E, Khalid N, Hideo-Kajita A, et al
    Paclitaxel-related balloons and stents for the treatment of peripheral artery disease: Insights from the Food and Drug Administration 2019 Circulatory System Devices Panel Meeting on late mortality.
    Am Heart J. 2020;222:112-120.
    PubMed     Abstract available


    March 2020
  47. YOON YH, Ahn JM, Kang DY, Park H, et al
    Pragmatic trial comparing routine versus no routine functional testing in high-risk patients who underwent percutaneous coronary intervention: Rationale and design of POST-PCI trial.
    Am Heart J. 2020;224:156-165.
    PubMed     Abstract available


  48. OSMAN M, Saleem M, Osman K, Kheiri B, et al
    Radial versus femoral access for percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction: Trial sequential analysis.
    Am Heart J. 2020;224:98-104.
    PubMed     Abstract available


  49. SMILOWITZ NR, Alviar CL, Katz SD, Hochman JS, et al
    Coronary artery bypass grafting versus percutaneous coronary intervention for myocardial infarction complicated by cardiogenic shock.
    Am Heart J. 2020 Mar 12. pii: S0002-8703(20)30080.
    PubMed     Abstract available


  50. VLACHOJANNIS GJ, Vogel RF, Wilschut JM, Lemmert ME, et al
    COMPARison of pre-hospital CRUSHed vs. uncrushed Prasugrel tablets in patients with STEMI undergoing primary percutaneous coronary interventions: Rationale and design of the COMPARE CRUSH trial.
    Am Heart J. 2020;224:10-16.
    PubMed     Abstract available


  51. VESELKA J
    Consequences of impressive myectomy results in a Center of Excellence: The paradox of evidence-based medicine era.
    Am Heart J. 2020;221:157-158.
    PubMed    


  52. G TOTH G, Lansky A, Baumbach A, Kelbaek H, et al
    Validation of the all-comers design: Results of the TARGET-AC substudy.
    Am Heart J. 2020;221:148-154.
    PubMed     Abstract available


    February 2020
  53. DAUBERT MA, White JA, Al-Khalidi HR, Velazquez EJ, et al
    Cardiac remodeling after large ST-elevation myocardial infarction in the current therapeutic era.
    Am Heart J. 2020;223:87-97.
    PubMed     Abstract available


  54. SONG L, Tu S, Sun Z, Wang Y, et al
    Quantitative flow ratio-guided strategy versus angiography-guided strategy for percutaneous coronary intervention: Rationale and design of the FAVOR III China trial.
    Am Heart J. 2020;223:72-80.
    PubMed     Abstract available


  55. JAWITZ OK, Gulack BC, Brennan JM, Thibault DP, et al
    Association of postoperative complications and outcomes following coronary artery bypass grafting.
    Am Heart J. 2020;222:220-228.
    PubMed     Abstract available


  56. D'ASCENZO F, Biole C, Raposeiras-Roubin S, Gaido F, et al
    Average daily ischemic versus bleeding risk in patients with ACS undergoing PCI: Insights from the BleeMACS and RENAMI registries.
    Am Heart J. 2020;220:108-115.
    PubMed     Abstract available


    January 2020
  57. ROMAGUERA R, Salinas P, Brugaletta S, Gomez-Lara J, et al
    Second-Generation Drug-Eluting Stents in Diabetes (SUGAR) trial: Rationale and study design.
    Am Heart J. 2020;222:174-182.
    PubMed    


  58. JEONG YJ, Park K, Kim YD
    Comparison between ticagrelor and clopidogrel on myocardial blood flow in patients with acute coronary syndrome, using 13 N-ammonia positron emission tomography.
    Am Heart J. 2020;222:121-130.
    PubMed     Abstract available


  59. KINNAIRD T, Gallagher S, Spratt JC, Ludman P, et al
    Complex high-risk and indicated percutaneous coronary intervention for stable angina: Does operator volume influence patient outcome?
    Am Heart J. 2020;222:15-25.
    PubMed     Abstract available


  60. NANNA MG, Peterson ED, Wu A, Harding T, et al
    Age, knowledge, preferences, and risk tolerance for invasive cardiac care.
    Am Heart J. 2020;219:99-108.
    PubMed     Abstract available


    December 2019
  61. PUYMIRAT E, Simon T, de Bruyne B, Montalescot G, et al
    Rationale and design of the Flow Evaluation to Guide Revascularization in Multivessel ST-Elevation Myocardial Infarction (FLOWER-MI) trial.
    Am Heart J. 2019;222:1-7.
    PubMed     Abstract available


  62. MCCOY IE, Montez-Rath ME, Chertow GM, Chang TI, et al
    Central venous pressure and the risk of diuretic-associated acute kidney injury in patients after cardiac surgery.
    Am Heart J. 2019;221:67-73.
    PubMed     Abstract available


  63. SHLOFMITZ E, Torguson R, Zhang C, Craig PE, et al
    Impact of Intravascular Ultrasound on Outcomes Following PErcutaneous Coronary InterventioN in Complex Lesions (iOPEN Complex).
    Am Heart J. 2019;221:74-83.
    PubMed     Abstract available


  64. WILLEMSEN LM, Janssen PWA, Hackeng CM, Kelder JC, et al
    A randomized, double-blind, placebo-controlled trial investigating the effect of ticagrelor on saphenous vein graft patency in patients undergoing coronary artery bypass grafting surgery-Rationale and design of the POPular CABG trial.
    Am Heart J. 2019;220:237-245.
    PubMed     Abstract available


  65. PATEL DM, Thiessen-Philbrook H, Brown JR, McArthur E, et al
    Association of plasma-soluble ST2 and galectin-3 with cardiovascular events and mortality following cardiac surgery.
    Am Heart J. 2019;220:253-263.
    PubMed     Abstract available


  66. RYMER JA, O'Donnell CI, Plomondon ME, Hess PL, et al
    Same-day discharge among patients undergoing elective PCI: Insights from the VA CART Program.
    Am Heart J. 2019;218:75-83.
    PubMed     Abstract available


    November 2019
  67. SUTTER JS, Lokhnygina Y, Daubert JP, Bahnson T, et al
    Safety and efficacy outcomes of left atrial posterior wall isolation compared to pulmonary vein isolation and pulmonary vein isolation with linear ablation for the treatment of persistent atrial fibrillation.
    Am Heart J. 2019;220:89-96.
    PubMed     Abstract available


  68. SHAVADIA JS, Granger CB, Alemayehu W, Westerhout CM, et al
    High-throughput targeted proteomics discovery approach and spontaneous reperfusion in ST-segment elevation myocardial infarction.
    Am Heart J. 2019;220:137-144.
    PubMed     Abstract available


  69. LONG CA, Zepel L, Greiner MA, Hammill BG, et al
    Use and 1-year outcomes with conventional and drug-coated balloon angioplasty in patients with lower extremity peripheral artery disease.
    Am Heart J. 2019;217:42-51.
    PubMed     Abstract available


    October 2019
  70. RYMER JA, Mandawat A, Abbott JD, Cohen MG, et al
    Opportunities for enhancing the care of older patients with ST-elevation myocardial infarction presenting for primary percutaneous coronary intervention: Rationale and design of the SAFE-STEMI for Seniors trial.
    Am Heart J. 2019;218:84-91.
    PubMed     Abstract available


  71. NIDORF SM, Fiolet ATL, Eikelboom JW, Schut A, et al
    The effect of low-dose colchicine in patients with stable coronary artery disease: The LoDoCo2 trial rationale, design, and baseline characteristics.
    Am Heart J. 2019;218:46-56.
    PubMed     Abstract available


  72. OHUCHI H, Negishi J, Hayama Y, Miike H, et al
    Abnormal glucose metabolism in patients with Fontan circulation: Unique characteristics and associations with Fontan pathophysiology.
    Am Heart J. 2019;216:125-135.
    PubMed     Abstract available


  73. JONES WS, Kennedy KF, Hawkins BM, Attaran RR, et al
    Expanding opportunities to understand quality and outcomes of peripheral vascular interventions: The ACC NCDR PVI Registry.
    Am Heart J. 2019;216:74-81.
    PubMed     Abstract available


    September 2019
  74. BRENNAN JM, Wruck L, Pencina MJ, Clare RM, et al
    Claims-based cardiovascular outcome identification for clinical research: Results from 7 large randomized cardiovascular clinical trials.
    Am Heart J. 2019;218:110-122.
    PubMed     Abstract available


  75. LOWENSTERN A, Wu J, Bradley SM, Fanaroff AC, et al
    Current landscape of hybrid revascularization: A report from the NCDR CathPCI Registry.
    Am Heart J. 2019;215:167-177.
    PubMed     Abstract available


    August 2019
  76. PARK S, Ahn JM, Lee K, Kwon O, et al
    Long-term (10-year) outcomes of stenting or bypass surgery for acute coronary syndromes and stable ischemic heart disease with unprotected left main coronary artery disease.
    Am Heart J. 2019;218:9-19.
    PubMed     Abstract available


  77. RAY KK, Nicholls SJ, Ginsberg HD, Johansson JO, et al
    Effect of selective BET protein inhibitor apabetalone on cardiovascular outcomes in patients with acute coronary syndrome and diabetes: Rationale, design, and baseline characteristics of the BETonMACE trial.
    Am Heart J. 2019;217:72-83.
    PubMed     Abstract available


  78. UDESEN NJ, Moller JE, Lindholm MG, Eiskjaer H, et al
    Rationale and design of DanGer shock: Danish-German cardiogenic shock trial.
    Am Heart J. 2019;214:60-68.
    PubMed     Abstract available


    July 2019
  79. RAMASAMY A, Serruys PW, Jones DA, Johnson TW, et al
    Reliable in vivo intravascular imaging plaque characterization: A challenge unmet.
    Am Heart J. 2019;218:20-31.
    PubMed     Abstract available


  80. SMILOWITZ NR, Lorin J, Berger JS
    Risks of noncardiac surgery early after percutaneous coronary intervention.
    Am Heart J. 2019;217:64-71.
    PubMed     Abstract available


  81. MAURI L, Doros G, Rao SV, Cohen DJ, et al
    The OPTIMIZE randomized trial to assess safety and efficacy of the Svelte IDS and RX Sirolimus-eluting coronary stent Systems for the Treatment of atherosclerotic lesions: Trial design and rationale.
    Am Heart J. 2019;216:82-90.
    PubMed     Abstract available


  82. FARIDI KF, Rymer JA, Rao SV, Dai D, et al
    Ad hoc percutaneous coronary intervention in patients with stable coronary artery disease: A report from the National Cardiovascular Data Registry CathPCI Registry.
    Am Heart J. 2019;216:53-61.
    PubMed     Abstract available


  83. PINA LM, Dong X, Zhang L, Samtani MN, et al
    Rivaroxaban, a direct Factor Xa inhibitor, versus acetylsalicylic acid as thromboprophylaxis in children post-Fontan procedure: Rationale and design of a prospective, randomized trial (the UNIVERSE study).
    Am Heart J. 2019;213:97-104.
    PubMed     Abstract available


  84. KONIGSTEIN M, Madhavan MV, Ben-Yehuda O, Rahim HM, et al
    Incidence and predictors of target lesion failure in patients undergoing contemporary DES implantation-Individual patient data pooled analysis from 6 randomized controlled trials.
    Am Heart J. 2019;213:105-111.
    PubMed     Abstract available


    June 2019
  85. MEHTA SR, Wood DA, Meeks B, Storey RF, et al
    Design and rationale of the COMPLETE trial: A randomized, comparative effectiveness study of complete versus culprit-only percutaneous coronary intervention to treat multivessel coronary artery disease in patients presenting with ST-segment elevation
    Am Heart J. 2019;215:157-166.
    PubMed     Abstract available


  86. CANNON CP, Khan I, Klimchak AC, Sanchez RJ, et al
    Simulation of impact on cardiovascular events due to lipid-lowering therapy intensification in a population with atherosclerotic cardiovascular disease.
    Am Heart J. 2019;216:30-41.
    PubMed     Abstract available


  87. GIBLETT JP, Clarke S, Zhao T, McCormick LM, et al
    The role of Glucagon-Like Peptide 1 Loading on periprocedural myocardial infarction During elective PCI (GOLD-PCI study): A randomized, placebo-controlled trial.
    Am Heart J. 2019;215:41-51.
    PubMed     Abstract available


  88. BAMFORD P, Lau GT
    One database, 2 studies, and a trebling of atherectomy rates.
    Am Heart J. 2019;212:157.
    PubMed    


    May 2019
  89. CLAEYS MJ, Coussement P, Dubois P, Garcia-Dorado D, et al
    Clinical effects of cyclosporine in acute anterior myocardial infarction complicated by heart failure: A subgroup analysis of the CIRCUS Trial.
    Am Heart J. 2019 May 30. pii: S0002-8703(19)30129.
    PubMed    


  90. TOTH G, Brodmann M, Barbato E, Mangiacapra F, et al
    Rational and design of the INtentional COronary revascularization versus conservative therapy in patients undergOing successful peripheRAl arTEry revascularization due to critical limb ischemia trial (INCORPORATE trial).
    Am Heart J. 2019;214:107-112.
    PubMed     Abstract available


  91. PUYMIRAT E, Cayla G, Cottin Y, Elbaz M, et al
    Twenty-year trends in profile, management and outcomes of patients with ST-segment elevation myocardial infarction according to use of reperfusion therapy: Data from the FAST-MI program 1995-2015.
    Am Heart J. 2019;214:97-106.
    PubMed     Abstract available


  92. ALEXANDRE J, Ollitrault P, Fischer MO, Fellahi JL, et al
    Spironolactone and perioperative atrial fibrillation occurrence in cardiac surgery patients: Rationale and design of the ALDOCURE trial.
    Am Heart J. 2019;214:88-96.
    PubMed     Abstract available


  93. GELMAN A, Carlin JB, Nallamothu BK
    Objective Randomised Blinded Investigation With Optimal Medical Therapy of Angioplasty in Stable Angina (ORBITA) and coronary stents: A case study in the analysis and reporting of clinical trials.
    Am Heart J. 2019;214:54-59.
    PubMed    


  94. DOUCET S, Jolicoeur EM, Serruys PW, Ragosta M 3rd, et al
    Outcomes of left main revascularization in patients with acute coronary syndromes and stable ischemic heart disease: Analysis from the EXCEL trial.
    Am Heart J. 2019;214:9-17.
    PubMed     Abstract available


    April 2019
  95. ZIMMERMANN FM, De Bruyne B, Pijls NHJ, Desai M, et al
    A protocol update of the Fractional Flow Reserve versus Angiography for Multivessel Evaluation (FAME) 3 trial: A comparison of fractional flow reserve-guided percutaneous coronary intervention and coronary artery bypass graft surgery in patients with
    Am Heart J. 2019;214:156-157.
    PubMed    


  96. QINTAR M, Hirai T, Arnold SV, Sheehy J, et al
    De-escalation of antianginal medications after successful chronic total occlusion percutaneous coronary intervention: Frequency and relationship with health status.
    Am Heart J. 2019;214:1-8.
    PubMed     Abstract available


  97. SULLIVAN LT 2ND, Mulder H, Chiswell K, Shaw LK, et al
    Racial differences in long-term outcomes among black and white patients with drug-eluting stents.
    Am Heart J. 2019;214:46-53.
    PubMed     Abstract available


  98. GUTIERREZ JA, Bhatt DL, Banerjee S, Glorioso TJ, et al
    Risk of obstructive coronary artery disease and major adverse cardiac events in patients with noncoronary atherosclerosis: Insights from the Veterans Affairs Clinical Assessment, Reporting, and Tracking (CART) Program.
    Am Heart J. 2019;213:47-56.
    PubMed     Abstract available


  99. VAN ZANDVOORT LJC, Masdjedi K, Tovar Forero MN, Lenzen MJ, et al
    Fractional flow reserve guided percutaneous coronary intervention optimization directed by high-definition intravascular ultrasound versus standard of care: Rationale and study design of the prospective randomized FFR-REACT trial.
    Am Heart J. 2019;213:66-72.
    PubMed     Abstract available


    March 2019
  100. JENSEN LO, Maeng M, Raungaard B, Engstrom T, et al
    Comparison of the polymer-free biolimus-coated BioFreedom stent with the thin-strut biodegradable polymer sirolimus-eluting Orsiro stent in an all-comers population treated with percutaneous coronary intervention: Rationale and design of the randomize
    Am Heart J. 2019;213:1-7.
    PubMed     Abstract available


  101. KIM C, Hong SJ, Shin DH, Kim BK, et al
    Randomized evaluation of ticagrelor monotherapy after 3-month dual-antiplatelet therapy in patients with acute coronary syndrome treated with new-generation sirolimus-eluting stents: TICO trial rationale and design.
    Am Heart J. 2019;212:45-52.
    PubMed     Abstract available


  102. YUDI MB, Clark DJ, Farouque O, Andrianopoulos N, et al
    Trends and predictors of recurrent acute coronary syndrome hospitalizations and unplanned revascularization after index acute myocardial infarction treated with percutaneous coronary intervention.
    Am Heart J. 2019;212:134-143.
    PubMed     Abstract available


  103. FRIGOLI E, Smits P, Vranckx P, Ozaki Y, et al
    Design and rationale of the Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Standard DAPT Regimen (MASTER DAPT) Study.
    Am Heart J. 2019;209:97-105.
    PubMed     Abstract available


  104. ELMARIAH S, Ansel GM, Brodmann M, Doros G, et al
    Design and rationale of a randomized noninferiority trial to evaluate the SurVeil drug-coated balloon in subjects with stenotic lesions of the femoropopliteal artery - the TRANSCEND study.
    Am Heart J. 2019;209:88-96.
    PubMed     Abstract available


  105. LIP GYH, Mauri L, Montalescot G, Ozkor M, et al
    Relationship of stroke and bleeding risk profiles to efficacy and safety of dabigatran dual therapy versus warfarin triple therapy in atrial fibrillation after percutaneous coronary intervention: An ancillary analysis from the RE-DUAL PCI trial.
    Am Heart J. 2019;212:13-22.
    PubMed     Abstract available


    February 2019
  106. WHITE L, Vlok R, Melhuish T
    Ultrasound-guided radial artery catheterization: A superior technique for expert clinicians?
    Am Heart J. 2019 Feb 23. pii: S0002-8703(19)30024.
    PubMed    


  107. MOUSSA PACHA H, Alraies MC
    In response to letter to the Editor: "Ultrasound guided radial artery catheterization: A superior technique for expert clinicians?"
    Am Heart J. 2019 Feb 23. pii: S0002-8703(19)30025.
    PubMed    


  108. FINN MT, Redfors B, Karmpaliotis D, Kirtane AJ, et al
    Adverse events in patients with high platelet reactivity following successful chronic total occlusion PCI: The Assessment of Dual AntiPlatelet Therapy with Drug-Eluting Stents (ADAPT-DES) study.
    Am Heart J. 2019;211:68-76.
    PubMed     Abstract available


  109. BULLUCK H, Frohlich GM, Nicholas JM, Mohdnazri S, et al
    Mineralocorticoid receptor antagonist pre-treatment and early post-treatment to minimize reperfusion injury after ST-elevation myocardial infarction: The MINIMIZE STEMI trial.
    Am Heart J. 2019;211:60-67.
    PubMed     Abstract available


    January 2019
  110. BLAKE SR, Shahzad A, Aggarwal SK, Kumar A, et al
    Radial versus femoral vascular access in ST-elevation myocardial infarction: Are the results of femoral operators unfairly represented in observational research?
    Am Heart J. 2019;210:81-87.
    PubMed     Abstract available


  111. FERRARI R, Ford I, Fox K, Marzilli M, et al
    A randomized, double-blind, placebo-controlled trial to assess the efficAcy and safety of Trimetazidine in patients with angina pectoris having been treated by percutaneous coronary intervention (ATPCI study): Rationale, design, and baseline character
    Am Heart J. 2019;210:98-107.
    PubMed     Abstract available


  112. ISRAELI Z, Lavi S, Pancholy SB, Nombela-Franco L, et al
    Radial versus femoral approach for saphenous vein grafts angiography and interventions.
    Am Heart J. 2019;210:1-8.
    PubMed     Abstract available


  113. KOSMIDOU I, Redfors B, Chen S, Crowley A, et al
    C-reactive protein and prognosis after percutaneous coronary intervention and bypass graft surgery for left main coronary artery disease: Analysis from the EXCEL trial.
    Am Heart J. 2019;210:49-57.
    PubMed     Abstract available


    December 2018
  114. WANG X, Tian M, Zheng Z, Gao H, et al
    Rationale and design of a multicenter randomized trial to compare the graft patency between no-touch vein harvesting technique and conventional approach in coronary artery bypass graft surgery.
    Am Heart J. 2018;210:75-80.
    PubMed     Abstract available


    November 2018
  115. HELD C, White HD, Stewart RAH, Davies R, et al
    Characterization of cardiovascular clinical events and impact of event adjudication on the treatment effect of darapladib versus placebo in patients with stable coronary heart disease: Insights from the STABILITY trial.
    Am Heart J. 2018;208:65-73.
    PubMed     Abstract available


  116. POLCWIARTEK C, Behrndtz P, Andersen AH, Bregendahl M, et al
    Attitudes and considerations of patients with ST-elevation myocardial infarction toward participation in randomized clinical trials.
    Am Heart J. 2018;208:21-27.
    PubMed    


    October 2018
  117. MUNKHAUGEN J, Ruddox V, Halvorsen S, Dammen T, et al
    BEtablocker Treatment After acute Myocardial Infarction in revascularized patients without reduced left ventricular ejection fraction (BETAMI): Rationale and design of a prospective, randomized, open, blinded end point study.
    Am Heart J. 2018;208:37-46.
    PubMed     Abstract available


    September 2018
  118. EYSENCK W, van Zalen J, Freemantle N, Lloyd G, et al
    Central arteriovenous anastomosis for the treatment of patients with uncontrolled hypertension and paroxysmal AF.
    Am Heart J. 2018 Sep 29. pii: S0002-8703(18)30279.
    PubMed     Abstract available


  119. GUEDENEY P, Baber U, Claessen B, Aquino M, et al
    Temporal trends, determinants, and impact of high-intensity statin prescriptions after percutaneous coronary intervention: Results from a large single-center prospective registry.
    Am Heart J. 2018;207:10-18.
    PubMed     Abstract available


  120. HARRISON RW, Radhakrishnan V, Allen JC Jr, Lam PS, et al
    The East-West late lumen loss study: Comparison of angiographic late lumen loss between Eastern and Western drug-eluting stent study cohorts.
    Am Heart J. 2018;206:61-71.
    PubMed     Abstract available


    August 2018
  121. MAURI L, Kirtane AJ, Windecker S, Yeh RW, et al
    Rationale and design of the EVOLVE Short DAPT Study to assess 3-month dual antiplatelet therapy in subjects at high risk for bleeding undergoing percutaneous coronary intervention.
    Am Heart J. 2018;205:110-117.
    PubMed     Abstract available


  122. EINDHOVEN DC, Wu HW, Kremer SWF, van Erkelens JA, et al
    Mortality differences in acute myocardial infarction patients in the Netherlands: The weekend-effect.
    Am Heart J. 2018;205:70-76.
    PubMed    


  123. CHUNG CJ, Kirtane AJ, Zhang Y, Witzenbichler B, et al
    Impact of high on-aspirin platelet reactivity on outcomes following successful percutaneous coronary intervention with drug-eluting stents.
    Am Heart J. 2018;205:77-86.
    PubMed     Abstract available


  124. LAURSEN PN, Holmvang L, Lonborg J, Kober L, et al
    Comparison between patients included in randomized controlled trials of ischemic heart disease and real-world data. A nationwide study.
    Am Heart J. 2018;204:128-138.
    PubMed     Abstract available


    July 2018
  125. BURGESS SN, French JK, Nguyen TL, Leung M, et al
    The impact of incomplete revascularization on early and late outcomes in ST-elevation myocardial infarction.
    Am Heart J. 2018;205:31-41.
    PubMed     Abstract available


  126. FUDIM M, Loungani R, Doerfler SM, Coles A, et al
    Worsening renal function during decongestion among patients hospitalized for heart failure: Findings from the Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE) trial.
    Am Heart J. 2018;204:163-173.
    PubMed     Abstract available


  127. GIBBONS RJ, Weintraub WS, Brindis RG
    Moving from volume to value for revascularization in stable ischemic heart disease: A review.
    Am Heart J. 2018 Jul 10. pii: S0002-8703(18)30108.
    PubMed     Abstract available


  128. HUGELSHOFER S, Roffi M, Witassek F, Eberli FR, et al
    Impact of total ischemic time on manual thrombus aspiration benefit during primary percutaneous coronary intervention.
    Am Heart J. 2018;204:34-42.
    PubMed     Abstract available


  129. VENETSANOS D, Lawesson SS, James S, Koul S, et al
    Bivalirudin versus heparin with primary percutaneous coronary intervention.
    Am Heart J. 2018;201:9-16.
    PubMed     Abstract available


    June 2018
  130. MOUSSA PACHA H, Alahdab F, Al-Khadra Y, Idris A, et al
    Ultrasound-guided versus palpation-guided radial artery catheterization in adult population: A systematic review and meta-analysis of randomized controlled trials.
    Am Heart J. 2018;204:1-8.
    PubMed     Abstract available


  131. CHI G, Kerneis M, Kalayci A, Liu Y, et al
    Safety and efficacy of non-vitamin K oral anticoagulant for atrial fibrillation patients after percutaneous coronary intervention: A bivariate analysis of the PIONEER AF-PCI and RE-DUAL PCI trial.
    Am Heart J. 2018;203:17-24.
    PubMed     Abstract available


  132. LOPES RD, Vora AN, Liaw D, Granger CB, et al
    An open-Label, 2 x 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention:
    Am Heart J. 2018;200:17-23.
    PubMed     Abstract available


  133. CAPLICE NM, DeVoe MC, Choi J, Dahly D, et al
    Randomized placebo controlled trial evaluating the safety and efficacy of single low-dose intracoronary insulin-like growth factor following percutaneous coronary intervention in acute myocardial infarction (RESUS-AMI).
    Am Heart J. 2018;200:110-117.
    PubMed     Abstract available


    May 2018
  134. JAKOBSEN L, Christiansen EH, Maeng M, Kristensen SD, et al
    Randomized clinical comparison of the dual-therapy CD34 antibody-covered sirolimus-eluting Combo stent with the sirolimus-eluting Orsiro stent in patients treated with percutaneous coronary intervention: Rationale and study design of the Scandinavian
    Am Heart J. 2018;202:49-53.
    PubMed     Abstract available


  135. KANG J, Koo BK, Hu X, Lee JM, et al
    Comparison of Fractional FLow Reserve And Intravascular ultrasound-guided Intervention Strategy for Clinical OUtcomes in Patients with InteRmediate Stenosis (FLAVOUR): Rationale and design of a randomized clinical trial.
    Am Heart J. 2018;199:7-12.
    PubMed     Abstract available


  136. GHARACHOLOU SM, Ijioma NN, Lennon RJ, Rihal CS, et al
    Characteristics and long term outcomes of patients with acute coronary syndromes due to culprit left main coronary artery disease treated with percutaneous coronary intervention.
    Am Heart J. 2018;199:156-162.
    PubMed     Abstract available


  137. WANG A, Wu A, Wojdyla D, Lopes RD, et al
    Dual antiplatelet therapy for perioperative myocardial infarction following CABG surgery.
    Am Heart J. 2018;199:150-155.
    PubMed     Abstract available


  138. VETROVEC GW, Anderson M, Schreiber T, Popma J, et al
    The cVAD registry for percutaneous temporary hemodynamic support: A prospective registry of Impella mechanical circulatory support use in high-risk PCI, cardiogenic shock, and decompensated heart failure.
    Am Heart J. 2018;199:115-121.
    PubMed     Abstract available


    April 2018
  139. RYMER JA, Kaltenbach LA, Anstrom KJ, Fonarow GC, et al
    Hospital evaluation of health literacy and associated outcomes in patients after acute myocardial infarction.
    Am Heart J. 2018;198:97-107.
    PubMed     Abstract available


  140. BATCHELOR W, Dahya V, McGee D, Katopodis J, et al
    Ultrahigh-resolution ultrasound characterization of access site trauma and intimal hyperplasia following use of a 7F sheathless guide versus 6F sheath/guide combination for transradial artery PCI: Results of the PRAGMATIC trial.
    Am Heart J. 2018;198:75-83.
    PubMed     Abstract available


  141. KINNAIRD T, Cockburn J, Gallagher S, Choudhury A, et al
    Temporal changes in radial access use, associates and outcomes in patients undergoing PCI using rotational atherectomy between 2007 and 2014: results from the British Cardiovascular Intervention Society national database.
    Am Heart J. 2018;198:46-54.
    PubMed     Abstract available


  142. BISHAWI M, Hattler B, Almassi GH, Spertus JA, et al
    Preoperative factors associated with worsening in health-related quality of life following coronary artery bypass grafting in the Randomized On/Off Bypass (ROOBY) trial.
    Am Heart J. 2018;198:33-38.
    PubMed     Abstract available


  143. VAN DER HEIJDEN LC, Kok MM, Zocca P, Jessurun GAJ, et al
    Bioresorbable Polymer-Coated Orsiro Versus Durable Polymer-Coated Resolute Onyx Stents (BIONYX): Rationale and design of the randomized TWENTE IV multicenter trial.
    Am Heart J. 2018;198:25-32.
    PubMed     Abstract available


  144. BERWANGER O, de Barros E Silva PGM, Dall Orto FTC, de Andrade PB, et al
    Rationale and design of the Statins Evaluation in Coronary procedUres and REvascularization: The SECURE-PCI Trial.
    Am Heart J. 2018;198:129-134.
    PubMed     Abstract available


  145. EGBE A, Khan AR, Al-Otaibi M, Said SM, et al
    Outcomes of hospitalization in adults with Fontan palliation: The Mayo Clinic experience.
    Am Heart J. 2018;198:115-122.
    PubMed     Abstract available


    March 2018
  146. SHAVADIA JS, French W, Hellkamp AS, Thomas L, et al
    Comprehensive electrocardiogram-to-device time for primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: A report from the American Heart Association mission: Lifeline program.
    Am Heart J. 2018;197:9-17.
    PubMed     Abstract available


  147. SONG YB, Oh SK, Oh JH, Im ES, et al
    Rationale and design of the comparison between a P2Y12 inhibitor monotherapy versus dual antiplatelet therapy in patients undergoing implantation of coronary drug-eluting stents (SMART-CHOICE): A prospective multicenter randomized trial.
    Am Heart J. 2018;197:77-84.
    PubMed     Abstract available


  148. WONG YTA, Kang DY, Lee JB, Rha SW, et al
    Comparison of drug-eluting stents and drug-coated balloon for the treatment of drug-eluting coronary stent restenosis: A randomized RESTORE trial.
    Am Heart J. 2018;197:35-42.
    PubMed     Abstract available


  149. REDFORS B, Genereux P, Witzenbichler B, Maehara A, et al
    Percutaneous coronary intervention of lesions with in-stent restenosis: A report from the ADAPT-DES study.
    Am Heart J. 2018;197:142-149.
    PubMed     Abstract available


  150. KOPIN D, Jones WS, Sherwood MW, Wojdyla DM, et al
    Percutaneous coronary intervention and antiplatelet therapy in patients with atrial fibrillation receiving apixaban or warfarin: Insights from the ARISTOTLE trial.
    Am Heart J. 2018;197:133-141.
    PubMed     Abstract available


  151. HWANG D, Park KW, Lee JM, Rhee TM, et al
    Efficacy and safety of dual antiplatelet therapy after coronary stenting in patients with chronic kidney disease.
    Am Heart J. 2018;197:103-112.
    PubMed     Abstract available


    February 2018
  152. BAGAI A, Goodman SG, Cantor WJ, Vicaut E, et al
    Duration of ischemia and treatment effects of pre- versus in-hospital ticagrelor in patients with ST-segment elevation myocardial infarction: Insights from the ATLANTIC study.
    Am Heart J. 2018;196:56-64.
    PubMed     Abstract available


  153. EGBE A, Khan AR, Miranda WR, Ammash NM, et al
    Mechanism for temporal changes in exercise capacity after Fontan palliation: Role of Doppler echocardiography.
    Am Heart J. 2018;196:144-152.
    PubMed     Abstract available


  154. VEMULAPALLI S, Parikh K, Coeytaux R, Hasselblad V, et al
    Systematic review and meta-analysis of endovascular and surgical revascularization for patients with chronic lower extremity venous insufficiency and varicose veins.
    Am Heart J. 2018;196:131-143.
    PubMed     Abstract available


  155. SCIAHBASI A, Frigoli E, Sarandrea A, Calabro P, et al
    Determinants of radiation dose during right transradial access: Insights from the RAD-MATRIX study.
    Am Heart J. 2018;196:113-118.
    PubMed     Abstract available


  156. VRANCKX P, Lewalter T, Valgimigli M, Tijssen JG, et al
    Evaluation of the safety and efficacy of an edoxaban-based antithrombotic regimen in patients with atrial fibrillation following successful percutaneous coronary intervention (PCI) with stent placement: Rationale and design of the ENTRUST-AF PCI trial
    Am Heart J. 2018;196:105-112.
    PubMed     Abstract available


  157. KILIC S, Fabris E, Van't Hof AWJ, Hamm CW, et al
    Thrombus aspiration and prehospital ticagrelor administration in ST-elevation myocardial infarction: Findings from the ATLANTIC trial.
    Am Heart J. 2018;196:1-8.
    PubMed     Abstract available


    January 2018
  158. AFANA M, Gurm HS, Seth M, Frazier KM, et al
    Primary percutaneous coronary intervention at centers with and without on-site surgical support: Insights from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2).
    Am Heart J. 2018;195:99-107.
    PubMed     Abstract available


  159. EGBE A, Khan AR, Khan SF, Anavekar NS, et al
    Role of Doppler echocardiography for cardiac output assessment in Fontan patients.
    Am Heart J. 2018;195:91-98.
    PubMed     Abstract available


  160. LIU E, Hsueh L, Kim H, Vidovich MI, et al
    Global geographical variation in patient characteristics in percutaneous coronary intervention clinical trials: A systematic review and meta-analysis.
    Am Heart J. 2018;195:39-49.
    PubMed     Abstract available


    December 2017
  161. EGBE AC, Huntley GD, Connolly HM, Ammash NM, et al
    Outcomes of cardiac pacing in adult patients after a Fontan operation.
    Am Heart J. 2017;194:92-98.
    PubMed     Abstract available


  162. ILIESCU CA, Cilingiroglu M, Giza DE, Rosales O, et al
    "Bringing on the light" in a complex clinical scenario: Optical coherence tomography-guided discontinuation of antiplatelet therapy in cancer patients with coronary artery disease (PROTECT-OCT registry).
    Am Heart J. 2017;194:83-91.
    PubMed     Abstract available


  163. QADERDAN K, Vos GA, McAndrew T, Steg PG, et al
    Outcomes in elderly and young patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with bivalirudin versus heparin: Pooled analysis from the EUROMAX and HORIZONS-AMI trials.
    Am Heart J. 2017;194:73-82.
    PubMed     Abstract available


  164. INOHARA T, Numasawa Y, Higashi T, Ueda I, et al
    Predictors of high cost after percutaneous coronary intervention: A review from Japanese multicenter registry overviewing the influence of procedural complications.
    Am Heart J. 2017;194:61-72.
    PubMed     Abstract available


    November 2017
  165. LEE PH, Lee JY, Lee CW, Han S, et al
    Long-term outcomes of bypass grafting versus drug-eluting stenting for left main coronary artery disease: Results from the IRIS-MAIN registry.
    Am Heart J. 2017;193:76-83.
    PubMed     Abstract available


    October 2017
  166. DEHGHANI P, Lavoie A, Lavi S, Crawford JJ, et al
    Effects of ticagrelor versus clopidogrel on platelet function in fibrinolytic-treated STEMI patients undergoing early PCI.
    Am Heart J. 2017;192:105-112.
    PubMed     Abstract available


    September 2017
  167. GUDNADOTTIR GS, Andersen K, Thrainsdottir IS, James SK, et al
    Gender differences in coronary angiography, subsequent interventions, and outcomes among patients with acute coronary syndromes.
    Am Heart J. 2017;191:65-74.
    PubMed     Abstract available


  168. WEI J, Mehta PK, Grey E, Garberich RF, et al
    Sex-based differences in quality of care and outcomes in a health system using a standardized STEMI protocol.
    Am Heart J. 2017;191:30-36.
    PubMed     Abstract available


    August 2017
  169. PROIETTI M, Airaksinen KEJ, Rubboli A, Schlitt A, et al
    Time in therapeutic range and major adverse outcomes in atrial fibrillation patients undergoing percutaneous coronary intervention: The Atrial Fibrillation Undergoing Coronary Artery Stenting (AFCAS) registry.
    Am Heart J. 2017;190:86-93.
    PubMed     Abstract available


  170. PALMERINI T, Serruys P, Kappetein AP, Genereux P, et al
    Clinical outcomes with percutaneous coronary revascularization vs coronary artery bypass grafting surgery in patients with unprotected left main coronary artery disease: A meta-analysis of 6 randomized trials and 4,686 patients.
    Am Heart J. 2017;190:54-63.
    PubMed     Abstract available


    July 2017
  171. FROBERT O, Gotberg M, Angeras O, Jonasson L, et al
    Design and rationale for the Influenza vaccination After Myocardial Infarction (IAMI) trial. A registry-based randomized clinical trial.
    Am Heart J. 2017;189:94-102.
    PubMed     Abstract available


  172. OHUCHI H, Miyazaki A, Negishi J, Hayama Y, et al
    Hemodynamic determinants of mortality after Fontan operation.
    Am Heart J. 2017;189:9-18.
    PubMed     Abstract available


  173. ARIOTTI S, van Leeuwen M, Brugaletta S, Leonardi S, et al
    Rationale and design of the Hunting for the off-target propertIes of Ticagrelor on Endothelial function and other Circulating biomarkers in Humans (HI-TECH) trial.
    Am Heart J. 2017;189:128-136.
    PubMed     Abstract available


    June 2017
  174. BABER U, Sartori S, Aquino M, Kini A, et al
    Use of prasugrel vs clopidogrel and outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention in contemporary clinical practice: Results from the PROMETHEUS study.
    Am Heart J. 2017;188:73-81.
    PubMed     Abstract available


  175. WIDMER RJ, Allison TG, Lennon R, Lopez-Jimenez F, et al
    Digital health intervention during cardiac rehabilitation: A randomized controlled trial.
    Am Heart J. 2017;188:65-72.
    PubMed     Abstract available


  176. GOLDBERG DJ, Zak V, Goldstein BH, Chen S, et al
    Results of a phase I/II multi-center investigation of udenafil in adolescents after fontan palliation.
    Am Heart J. 2017;188:42-52.
    PubMed     Abstract available


  177. SELKER HP, Udelson JE, Ruthazer R, D'Agostino RB, et al
    Relationship between therapeutic effects on infarct size in acute myocardial infarction and therapeutic effects on 1-year outcomes: A patient-level analysis of randomized clinical trials.
    Am Heart J. 2017;188:18-25.
    PubMed     Abstract available


  178. ABNOUSI F, Sundaram V, Yong CM, Prats J, et al
    Cangrelor reduces the risk of ischemic complications in patients with single-vessel and multi-vessel disease undergoing percutaneous coronary intervention: Insights from the CHAMPION PHOENIX trial.
    Am Heart J. 2017;188:147-155.
    PubMed     Abstract available


  179. MELINA G, Angeloni E, Refice S, Monti F, et al
    Clinical SYNTAX score predicts outcomes of patients undergoing coronary artery bypass grafting.
    Am Heart J. 2017;188:118-126.
    PubMed     Abstract available


  180. KEDHI E, Fabris E, van der Ent M, Kennedy MW, et al
    A prospective, randomized, open-label trial of 6-month versus 12-month dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction: Rationale and design of the "DAPT-STEMI trial".
    Am Heart J. 2017;188:11-17.
    PubMed     Abstract available


    May 2017
  181. FENDER EA, Liang JJ, Sio TT, Stulak JM, et al
    Percutaneous revascularization in patients treated with thoracic radiation for cancer.
    Am Heart J. 2017;187:98-103.
    PubMed     Abstract available


  182. FINESCHI M, Verna E, Mezzapelle G, Bartolini D, et al
    Assessing MICRO-vascular resistances via IMR to predict outcome in STEMI patients with multivessel disease undergoing primary PCI (AMICRO): Rationale and design of a prospective multicenter clinical trial.
    Am Heart J. 2017;187:37-44.
    PubMed     Abstract available


  183. BAGAI A, Peterson ED, McCoy LA, Effron MB, et al
    Association of measured platelet reactivity with changes in P2Y12 receptor inhibitor therapy and outcomes after myocardial infarction: Insights into routine clinical practice from the TReatment with ADP receptor iNhibitorS: Longitudinal Assessment of
    Am Heart J. 2017;187:19-28.
    PubMed     Abstract available


  184. LEMMERT ME, Oldroyd K, Barragan P, Lesiak M, et al
    Reduced duration of dual antiplatelet therapy using an improved drug-eluting stent for percutaneous coronary intervention of the left main artery in a real-world, all-comer population: Rationale and study design of the prospective randomized multicent
    Am Heart J. 2017;187:104-111.
    PubMed     Abstract available


  185. SCIAHBASI A, Rigattieri S, Sarandrea A, Cera M, et al
    Determinants of operator radiation exposure during percutaneous coronary procedures.
    Am Heart J. 2017;187:10-18.
    PubMed     Abstract available


    April 2017
  186. SMITS PC, Assaf A, Richardt G, Omerovic E, et al
    Design and rationale of the COMPARE-ACUTE trial: Fractional flow reserve-guided primary multivessel percutaneous coronary intervention to improve guideline indexed actual standard of care for treatment of ST-elevation myocardial infarction in patients
    Am Heart J. 2017;186:21-28.
    PubMed     Abstract available


  187. EGBE AC, Connolly HM, Khan AR, Niaz T, et al
    Outcomes in adult Fontan patients with atrial tachyarrhythmias.
    Am Heart J. 2017;186:12-20.
    PubMed     Abstract available


  188. HANNAN EL, Zhong Y, Jacobs AK, Ling FSK, et al
    Incomplete revascularization for percutaneous coronary interventions: Variation among operators, and association with operator and hospital characteristics.
    Am Heart J. 2017;186:118-126.
    PubMed     Abstract available


    March 2017
  189. BAVISHI C, Sardar P, Chatterjee S, Khan AR, et al
    Intravascular ultrasound-guided vs angiography-guided drug-eluting stent implantation in complex coronary lesions: Meta-analysis of randomized trials.
    Am Heart J. 2017;185:26-34.
    PubMed     Abstract available


  190. LEE H, Koo BK, Park KW, Shin ES, et al
    A randomized clinical trial comparing long-term clopidogrel vs aspirin monotherapy beyond dual antiplatelet therapy after drug-eluting coronary stent implantation: Design and rationale of the Harmonizing Optimal Strategy for Treatment of coronary arte
    Am Heart J. 2017;185:17-25.
    PubMed     Abstract available


    February 2017
  191. ERNE P, Iglesias JF, Urban P, Eberli FR, et al
    Left bundle-branch block in patients with acute myocardial infarction: Presentation, treatment, and trends in outcome from 1997 to 2016 in routine clinical practice.
    Am Heart J. 2017;184:106-113.
    PubMed     Abstract available


    January 2017
  192. EGBE AC, Connolly HM, Niaz T, Yogeswaran V, et al
    Prevalence and outcome of thrombotic and embolic complications in adults after Fontan operation.
    Am Heart J. 2017;183:10-17.
    PubMed     Abstract available


  193. RIMAC G, Fearon WF, De Bruyne B, Ikeno F, et al
    Clinical value of post-percutaneous coronary intervention fractional flow reserve value: A systematic review and meta-analysis.
    Am Heart J. 2017;183:1-9.
    PubMed     Abstract available


    December 2016
  194. BABER U, Dangas G, Cohen DJ, Gibson CM, et al
    Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: Rationale and design of the TWILIGHT study.
    Am Heart J. 2016;182:125-134.
    PubMed     Abstract available


  195. GRODZINSKY A, Arnold SV, Wang TY, Sharma P, et al
    Bleeding risk following percutaneous coronary intervention in patients with diabetes prescribed dual anti-platelet therapy.
    Am Heart J. 2016;182:111-118.
    PubMed     Abstract available


  196. HARRISON RW, Radhakrishnan V, Lam PS, Allocco DJ, et al
    Rationale and design of the East-West late lumen loss study: Comparison of late lumen loss between Eastern and Western drug-eluting stent study cohorts.
    Am Heart J. 2016;182:103-110.
    PubMed     Abstract available


  197. LEE JM, Cho DK, Hahn JY, Song YB, et al
    Safety of 6-month duration of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndromes: Rationale and design of the Smart Angioplasty Research Team-safety of 6-month duration of Dual Antiplatelet The
    Am Heart J. 2016;182:1-8.
    PubMed     Abstract available


    November 2016
  198. YAKSH A, Kik C, Knops P, van Ettinger MJ, et al
    Early, de novo atrial fibrillation after coronary artery bypass grafting: Facts and features.
    Am Heart J. 2016;184:62-70.
    PubMed     Abstract available


  199. VEROUHIS D, Sorensson P, Gourine A, Henareh L, et al
    Effect of remote ischemic conditioning on infarct size in patients with anterior ST-elevation myocardial infarction.
    Am Heart J. 2016;181:66-73.
    PubMed     Abstract available


  200. PICCARO DE OLIVEIRA P, Gonzales V, Lopes RD, Schmidt MM, et al
    Serious infections among unselected patients with ST-elevation myocardial infarction treated with contemporary primary percutaneous coronary intervention.
    Am Heart J. 2016;181:52-59.
    PubMed     Abstract available


  201. DERY JP, Mehta SR, Fisher HN, Zhang X, et al
    Baseline characteristics, adenosine diphosphate receptor inhibitor treatment patterns, and in-hospital outcomes of myocardial infarction patients undergoing percutaneous coronary intervention in the prospective Canadian Observational AntiPlatelet sTud
    Am Heart J. 2016;181:26-34.
    PubMed     Abstract available


  202. FERRI LA, Morici N, Grosseto D, Tortorella G, et al
    A comparison of reduced-dose prasugrel and standard-dose clopidogrel in elderly patients with acute coronary syndromes undergoing early percutaneous revascularization: Design and rationale of the randomized Elderly-ACS 2 study.
    Am Heart J. 2016;181:101-106.
    PubMed     Abstract available


    October 2016
  203. AGARWAL SK, Kasula S, Almomani A, Hacioglu Y, et al
    Clinical and angiographic predictors of persistently ischemic fractional flow reserve after percutaneous revascularization.
    Am Heart J. 2016;184:10-16.
    PubMed     Abstract available


  204. SRA S, Tan MK, Mehta SR, Fisher HN, et al
    Ischemic and bleeding events in patients with myocardial infarction undergoing percutaneous coronary intervention who require oral anticoagulation: Insights from the Canadian observational AntiPlatelet sTudy.
    Am Heart J. 2016;180:82-9.
    PubMed     Abstract available


  205. KONTOS MC, Wang TY, Chen AY, Bates ER, et al
    The effect of high-risk ST elevation myocardial infarction transfer patients on risk-adjusted in-hospital mortality: A report from the American Heart Association Mission: Lifeline program.
    Am Heart J. 2016;180:74-81.
    PubMed     Abstract available


  206. LEMKES JS, Janssens GN, Straaten HM, Elbers PW, et al
    Coronary angiography after cardiac arrest: Rationale and design of the COACT trial.
    Am Heart J. 2016;180:39-45.
    PubMed     Abstract available


    September 2016
  207. MCNEELY C, Markwell S, Vassileva CM
    Readmission after inpatient percutaneous coronary intervention in the Medicare population from 2000 to 2012.
    Am Heart J. 2016;179:195-203.
    PubMed     Abstract available


  208. CHANG M, Ahn JM, Kim N, Lee PH, et al
    Complete versus incomplete revascularization in patients with multivessel coronary artery disease treated with drug-eluting stents.
    Am Heart J. 2016;179:157-65.
    PubMed     Abstract available


  209. DE WAHA A, Sandner S, von Scheidt M, Boening A, et al
    A randomized, parallel group, double-blind study of ticagrelor compared with aspirin for prevention of vascular events in patients undergoing coronary artery bypass graft operation: Rationale and design of the Ticagrelor in CABG (TiCAB) trial: An Inve
    Am Heart J. 2016;179:69-76.
    PubMed     Abstract available


  210. TANGUTURI VK, Wasfy JH
    Hospital readmissions after percutaneous coronary intervention aredeclining, but caution ahead is needed.
    Am Heart J. 2016;179:192-4.
    PubMed    


    August 2016
  211. DECKER C, Garavalia L, Garavalia B, Gialde E, et al
    Understanding physician-level barriers to the use of individualized risk estimates in percutaneous coronary intervention.
    Am Heart J. 2016;178:190-7.
    PubMed     Abstract available


  212. HARRISON RW, Simon D, Miller AL, de Lemos JA, et al
    Association of hospital myocardial infarction volume with adherence to American College of Cardiology/American Heart Association performance measures: Insights from the National Cardiovascular Data Registry.
    Am Heart J. 2016;178:95-101.
    PubMed     Abstract available


  213. CAMARO C, Damen SA, Brouwer MA, Kedhi E, et al
    Randomized evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: rationale and design of the REDUCE trial.
    Am Heart J. 2016;178:37-44.
    PubMed     Abstract available


  214. RAO C, Du J, Li X, Li J, et al
    Rationale and design of a randomized cluster trial to improve guideline-adherence of secondary preventive drugs prescription after coronary artery bypass grafting in China: Measurement and Improvement Studies of Surgical Coronary Revascularization: Se
    Am Heart J. 2016;178:9-18.
    PubMed     Abstract available


  215. ROTHBERG MB, Martinez KA
    Risky business: Personalizing the approach to percutaneous coronary intervention.
    Am Heart J. 2016;178:185-7.
    PubMed    


    July 2016
  216. DAYOUB EJ, Nallamothu BK
    Geographic access to transcatheter aortic valve replacement relative to other invasive cardiac services: A statewide analysis.
    Am Heart J. 2016;177:163-70.
    PubMed     Abstract available


  217. TING R, Tejpal A, Finken L, Fisher M, et al
    Repatriation to referral hospital after reperfusion of STEMI patients transferred for primary percutaneous coronary intervention: Insights of a Canadian regional STEMI care system.
    Am Heart J. 2016;177:145-52.
    PubMed     Abstract available


  218. NDREPEPA G, Iijima R, Kufner S, Braun S, et al
    Association of progression or regression of coronary artery atherosclerosis with long-term prognosis.
    Am Heart J. 2016;177:9-16.
    PubMed     Abstract available


  219. SHIMADA YJ, Bansilal S, Wiviott SD, Becker RC, et al
    Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial.
    Am Heart J. 2016;177:1-8.
    PubMed     Abstract available


    June 2016
  220. GRIMFJARD P, Erlinge D, Koul S, Lagerqvist B, et al
    Low real-world early stent thrombosis rates in ST-elevation myocardial infarction patients and the use of bivalirudin, heparin alone or glycoprotein IIb/IIIa inhibitor treatment: A nationwide Swedish registry report.
    Am Heart J. 2016;176:78-82.
    PubMed     Abstract available


  221. DE LUCA L, Capranzano P, Patti G, Parodi G, et al
    Switching of platelet P2Y12 receptor inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention: Review of the literature and practical considerations.
    Am Heart J. 2016;176:44-52.
    PubMed     Abstract available


  222. VAN DER HEIJDEN LC, Kok MM, Danse PW, Schramm AR, et al
    Small-vessel treatment with contemporary newer-generation drug-eluting coronary stents in all-comers: Insights from 2-year DUTCH PEERS (TWENTE II) randomized trial.
    Am Heart J. 2016;176:28-35.
    PubMed     Abstract available


  223. ANDERSON LL, Dai D, Miller AL, Roe MT, et al
    Percutaneous coronary intervention for older adults who present with syncope and coronary artery disease? Insights from the National Cardiovascular Data Registry.
    Am Heart J. 2016;176:1-9.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Vascular Surgery is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: